[
  {
    "ts": "2026-01-16T13:06:37+00:00",
    "headline": "Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026",
    "summary": "Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move. The fund’s structure is simple but powerful: it delivers three times the daily return of the S&P Biotechnology Select Industry Index through derivatives ... Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026",
    "url": "https://247wallst.com/investing/2026/01/16/triple-leveraged-biotech-etf-doubles-as-regulatory-winds-shift-in-2026/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7802d2c2-8d0a-37bb-8e11-c8a9c1049a84",
      "content": {
        "id": "7802d2c2-8d0a-37bb-8e11-c8a9c1049a84",
        "contentType": "STORY",
        "title": "Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026",
        "description": "",
        "summary": "Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move. The fund’s structure is simple but powerful: it delivers three times the daily return of the S&P Biotechnology Select Industry Index through derivatives ... Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026",
        "pubDate": "2026-01-16T13:06:37Z",
        "displayTime": "2026-01-16T13:06:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/05ba9404c915a419026e3b8982c7a175",
          "originalWidth": 1376,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ca_NwSOFjeoTqNqesLnZbg--~B/aD03Njg7dz0xMzc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/05ba9404c915a419026e3b8982c7a175.cf.webp",
              "width": 1376,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vRo5UNSb5f8YroscxSHfNQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/05ba9404c915a419026e3b8982c7a175.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/01/16/triple-leveraged-biotech-etf-doubles-as-regulatory-winds-shift-in-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/triple-leveraged-biotech-etf-doubles-130637787.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LABU"
            },
            {
              "symbol": "IBB"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "^SPSIBI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]